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INTRODUCTION
Pancreas cancer is one of the most aggressive hu-
man cancers. The overall 5-year survival rate among
patients with pancreatic cancer is5% (1). Cholan-
giocarcinoma is a cancer arising from bile duct epi-
thelium. This cancer is one of the most difficult dis-
eases to treat as pancreas cancer, and no standard
chemotherapy has been established (2, 3). There-
fore, we have researched about resistance of che-
motherapy in pancreatic and biliary tract cancers.
5-fluorouracil (5-FU) is a chemotherapeutic drug
which is widely used mainly for the treatment of
the digestive system cancer, but the response rate
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in pancreatic and biliary tract cancers is very low
(4, 5). Therefore, new agents and innovative ap-
proach to therapy are the important subjects for
research.
Alterations in the epigenetic modulation of gene
expression have been implicated in cancer devel-
opment and progression, and histone acetylation,
one of the epigenetic regulations, is a posttransla-
tional modulation of the nucleosomal histones that
affects chromatin structure and modulates gene ex-
pressions. Histone deacetylases (HDACs) comprise
an ancient family of enzymes that play crucial roles
in numerous biological processes (6), and HDACs
are found to be overexpressed in many tumor types
(7, 8). We reported that the survival rate for pan-
creas cancer patients with HDAC1-positive was sig-
nificantly lower than that for patients with HDAC1-
negative, and HDAC1 was considered to be a prom-
ising therapeutic target in pancreas cancer (9).
HDAC inhibitors induce the differentiation or apop-
tosis of cancer cells (10, 11). Therefore, HDAC in-
hibitors are promising new agents, in this study, we
used Valproic acid (VPA). VPA has the antitumor
effects of a HDAC inhibitor (12), and VPA has been
shown to have anticancer effects in various cancer
models (13).
The aim of this study was to investigate the anti-
cancer effects of VPA in combination with 5-FU in
pancreas cancer and cholangiocarcinoma cell lines.
MATERIAL AND METHOD
Cell lines and culture conditions
SUIT-2 cell was purchased from the Japanese
Collection Research Bioresources Cell Bank (Tokyo,
Japan). HuCCT-1 was provided by the RIKEN BRC
through the National Bio-Resource Project of the
MEXT, Japan. All cell lines were grown in RPMI
1640 supplemented with 10% fetal bovine serum
(FBS), 70 μg/mL penicillin and 100 μg/mL strepto-
mycin (complete medium) and maintained at 37
in a humidiWed incubator with 5% CO2 in air. The
cells were maintained for no longer than 12 weeks
after recovery from frozen stock.
Reagents
Valproic acid was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan), and kept
at 4and diluted in PBS as necessary at the time
of use. 5-FU was purchased from Kyowa Hakko
(Tokyo, Japan) and made fresh in 0.9% NaCl on the
day of use.
Cell proliferation assay
All of tumor cells (5103) were seeded into 38-
mm2 wells of flat-bottomed 96-well plates in quad-
ruplicate and allowed to adhere overnight. The spent
medium was then removed, and the cultures were
refed with new medium (negative control) or me-
dium containing diVerent concentrations of VPA and
5-FU. Incubation was continued for 72 h prior to
adding the Cell Counting Kit-8, and after 2 h, the
optical density was measured at 450 nm with a mi-
croplate reader (Multiskan JX ; Labsystems).
Statistical analyses
Statistical comparisons of mean values were con-
ducted using oneway ANOVA. All the results are
presented as meanSD. Statistical analysis was per-
formed using Stat View 5.0 J software (SAS Institute,
Inc., Cary, NC, USA). A P value of less than 0.05
was considered to be statistically significant.
RESULTS
In pancreas cancer cell line, SUIT-2, no effect of
5-FU was observed in dose of 1.0 μM and 17%, 30%
and 33% of proliferation-inhibitory effects were ob-
served in dose of 2.5, 5.0 and 10 μM (Fig. 1A). VPA
(0.5 mM) weakly decreased cell viability by 13%,
and VPA (1.0 mM) suppressed by 19% (Fig. 1B). In
combination of 5-FU and VPA, 19% of inhibitory ef-
fect was observed in dose of 5-FU 1.0 μM/VPA 0.5
mM, the combination effect was significant compare
Figure 1 : The effect of 5-FU (A), VPA (B) and combination of
5-FU and VPA (C) in inhibiting cell proliferation of human pan-
creas cancer cell line, SUIT-2.
** : p0.05, * : p0.01.
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to 5-FU alone or VPA alone (P0.01) (Fig. 1C).
In cholangiocarcinoma cell line, 5-FU (1.0 μM)
did not suppress the cell viability, 5-FU (2.5 μM)
suppressed by 23%, and 34% and 39% of proliferation-
inhibitory effects were observed in dose of 5.0 and
10 μM (Fig. 2A). VPA (0.5 mM) did not suppress
the cell viability, while VPA (1.0 mM) weakly de-
creased it by 11% (Fig. 2B). 5-FU (1.0 μM) and
VPA (0.5 mM) reduced by 30%, which significantly
augmented the anticancer effect of 5-FU alone or
VPA alone (P0.01) (Fig. 2C).
DISCUSSION
In the present study, we assessed the effect of
HDAC inhibitor (VPA) in combination with 5-FU
on pancreatic-biliary carcinoma cell lines. To our
knowledge, this is the first report to show that VPA
enhances the effect of 5-FU on both pancreas can-
cer and cholangiocarcinoma cell lines.
HDAC inhibitors are useful in cancer treatment
when used in combination with current chemothera-
peutic drugs, especially in combination with 5-FU,
HDAC inhibitor (MS275) enhance the effect of 5-
FU in colorectal cancer cells (14), and other HDAC
inhibitor (SAHA) enhance the effect of 5-FU in non-
small cell lung cancer (15). The mechanisms of the
additional effects on HDAC inhibitors to the cyto-
toxic agent are the enhancement of apoptosis (14)
and the up-regulation of p21(waf1/cip1) expression
(15). In this study, the mechanisms may be the aug-
mentation of apoptosis or the enhancement of p21
(waf1/cip1) expression.
However, some HDAC inhibitors are of limited
therapeutic use due to toxic side effects at high
doses (16). VPA is widely used as a therapeutic
drug for epilepsy, its toxicity profile and pharmacoki-
netic properties are well established. Furthermore,
in our study, the dose of VPA was 0.5 mM, because
the peak plasma concentration in patients treated
for epilepsy ranges between 0.5 and 1.2 mM (17).
VPA at a dose of 0.5 mM may not cause any seri-
ous side effects in clinical setting.
Recently, S-1, an oral drug consisting of the 5-
FU prodrug tegafur, combined with two modulators
of 5-FU activity, has been developed (18-20). S-1
contains 5-chloro-2,4-dihydroxypyridine (CDHP),
CDHP competitively inhibits the 5-FU degradative
enzyme dihydropyrimidine dehydrogenase (DPD),
resulting in the retention of a prolonged concentra-
tion of 5-FU in blood (18).
VPA has been investigated in clinical studies (21,
22), we plan the clinical trial of the combination ther-
apy, S-1 and VPA. We have expected VPA enhances
the anti-tumor effect of S-1 in this trial.
In conclusion, VPA augmented the inhibitory ef-
fects of 5-FU on the proliferation rates of both pan-
creas cancer and cholangiocarcinoma cell lines.
Therefore, VPA in combination with 5-FU is sug-
gested to be a promising therapeutic option for pan-
creatic and biliary tract cancers.
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